EA201600507A2 - Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr - Google Patents

Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr

Info

Publication number
EA201600507A2
EA201600507A2 EA201600507A EA201600507A EA201600507A2 EA 201600507 A2 EA201600507 A2 EA 201600507A2 EA 201600507 A EA201600507 A EA 201600507A EA 201600507 A EA201600507 A EA 201600507A EA 201600507 A2 EA201600507 A2 EA 201600507A2
Authority
EA
Eurasian Patent Office
Prior art keywords
indol
egfr
oxo
methylene
methyl
Prior art date
Application number
EA201600507A
Other languages
English (en)
Other versions
EA201600507A3 (ru
EA032217B1 (ru
Inventor
Майкл Бёрбридж
Валери Каттан
Анне Жаке-Бескон
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201600507(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of EA201600507A2 publication Critical patent/EA201600507A2/ru
Publication of EA201600507A3 publication Critical patent/EA201600507A3/ru
Publication of EA032217B1 publication Critical patent/EA032217B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Сочетание 3-[(3-{[4-(4-морфолинилметил)-1Н-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1Н-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона формулы (I)или его Z или Е изомеров, и/или его аддитивной соли с фармацевтически приемлемой кислотой или основанием и ингибитора тирозинкиназы рецептора эпидермального фактора роста человека (EGFR). Лекарственные средства.
EA201600507A 2015-07-31 2016-07-29 Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr EA032217B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1557412A FR3039401B1 (fr) 2015-07-31 2015-07-31 Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Publications (3)

Publication Number Publication Date
EA201600507A2 true EA201600507A2 (ru) 2017-02-28
EA201600507A3 EA201600507A3 (ru) 2017-03-31
EA032217B1 EA032217B1 (ru) 2019-04-30

Family

ID=55299545

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600507A EA032217B1 (ru) 2015-07-31 2016-07-29 Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr

Country Status (40)

Country Link
US (1) US20170027952A1 (ru)
EP (1) EP3124025B1 (ru)
JP (2) JP2017061445A (ru)
KR (1) KR101822492B1 (ru)
CN (1) CN106397427A (ru)
AR (1) AR105527A1 (ru)
AU (1) AU2016206300A1 (ru)
BR (1) BR102016017404A2 (ru)
CA (1) CA2936904C (ru)
CL (1) CL2018000256A1 (ru)
CO (1) CO2018000953A2 (ru)
CR (1) CR20180044A (ru)
CU (1) CU20180013A7 (ru)
CY (1) CY1120792T1 (ru)
DK (1) DK3124025T3 (ru)
EA (1) EA032217B1 (ru)
EC (1) ECSP18003671A (ru)
ES (1) ES2671133T3 (ru)
FR (1) FR3039401B1 (ru)
HR (1) HRP20180760T1 (ru)
HU (1) HUE037632T2 (ru)
IL (1) IL257232A (ru)
LT (1) LT3124025T (ru)
MA (1) MA39693B1 (ru)
MD (1) MD3124025T2 (ru)
ME (1) ME03052B (ru)
MX (1) MX366748B (ru)
NO (1) NO3124025T3 (ru)
PE (1) PE20190350A1 (ru)
PH (1) PH12016000248A1 (ru)
PL (1) PL3124025T3 (ru)
PT (1) PT3124025T (ru)
RS (1) RS57057B1 (ru)
RU (1) RU2695362C2 (ru)
SG (1) SG10201605664SA (ru)
SI (1) SI3124025T1 (ru)
SV (1) SV2018005615A (ru)
TN (1) TN2018000028A1 (ru)
TW (1) TWI623315B (ru)
WO (1) WO2017021634A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101956978B1 (ko) * 2015-05-18 2019-03-12 주식회사 케이티 시스템 정보 송수신 방법 및 그 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034776A1 (en) * 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
RS52351B (en) * 2007-03-01 2012-12-31 Novartis Ag 5- (2,4-Dihydroxy-5-isopropyl-phenyl) -4- (4-morpholine-4-ylmethyl-phenyl) -isoxazole-3-carboxylic acid ethylamide mesylate, their hydrates and polymorphs, and formulations thereof
CA2680161A1 (en) * 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5945863B2 (ja) * 2012-01-06 2016-07-05 国立大学法人高知大学 腎細胞がん治療剤
CN105246511A (zh) * 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
WO2015104043A1 (en) * 2014-01-07 2015-07-16 Merck Patent Gmbh Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
WO2016055916A1 (en) * 2014-10-06 2016-04-14 Novartis Ag Therapeutic combination for the treatment of cancer

Also Published As

Publication number Publication date
JP2017061445A (ja) 2017-03-30
SI3124025T1 (en) 2018-04-30
TN2018000028A1 (fr) 2019-07-08
CN106397427A (zh) 2017-02-15
MX366748B (es) 2019-07-23
US20170027952A1 (en) 2017-02-02
KR101822492B1 (ko) 2018-01-29
SG10201605664SA (en) 2017-02-27
RU2695362C2 (ru) 2019-07-23
ES2671133T3 (es) 2018-06-05
EP3124025B1 (fr) 2018-02-28
ECSP18003671A (es) 2018-03-31
FR3039401B1 (fr) 2018-07-13
TWI623315B (zh) 2018-05-11
RS57057B1 (sr) 2018-05-31
IL257232A (en) 2018-03-29
CY1120792T1 (el) 2019-12-11
NO3124025T3 (ru) 2018-07-28
HRP20180760T1 (hr) 2018-06-15
CL2018000256A1 (es) 2018-04-06
RU2016131395A3 (ru) 2018-06-08
CR20180044A (es) 2018-04-03
EA201600507A3 (ru) 2017-03-31
LT3124025T (lt) 2018-03-26
DK3124025T3 (en) 2018-06-06
ME03052B (me) 2018-10-20
PT3124025T (pt) 2018-04-09
CO2018000953A2 (es) 2018-07-10
PE20190350A1 (es) 2019-03-07
MD3124025T2 (ro) 2018-06-30
FR3039401A1 (fr) 2017-02-03
BR102016017404A2 (pt) 2017-02-07
JP2019163306A (ja) 2019-09-26
TW201711686A (zh) 2017-04-01
PH12016000248A1 (en) 2018-01-22
MX2016009743A (es) 2017-03-03
MA39693B1 (fr) 2018-07-31
SV2018005615A (es) 2018-05-14
PL3124025T3 (pl) 2018-06-29
EP3124025A1 (fr) 2017-02-01
EA032217B1 (ru) 2019-04-30
KR20170015218A (ko) 2017-02-08
CA2936904C (fr) 2018-12-04
CA2936904A1 (fr) 2017-01-31
CU20180013A7 (es) 2018-05-08
AR105527A1 (es) 2017-10-11
RU2016131395A (ru) 2018-02-02
WO2017021634A1 (fr) 2017-02-09
MA39693A (fr) 2017-02-01
AU2016206300A1 (en) 2017-02-16
HUE037632T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
CY1125110T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
BR112016008849B8 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
MX2016001011A (es) Derivados de quinazolin-4-ona sustituida.
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
WO2014055928A3 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
WO2014055934A3 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA202091279A1 (ru) Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их получения
EA201600507A2 (ru) Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr
EA202091691A1 (ru) ТВЕРДЫЕ ФОРМЫ ЗАМЕЩЕННЫХ 5,6-ДИГИДРО-6-ФЕНИЛБЕНЗО[f]ИЗОХИНОЛИН-2-АМИНОВЫХ СОЕДИНЕНИЙ
CY1119259T1 (el) Νεο αλας της 3-[(3-{[4-(4-μορφολινυλμεθυλ)-1η-πυρρολ-2-υλ]μεθυλενο}-2-οξο-2,3-διϋδρο-1η-ινδολ-5-υλ)μεθυλ]-1,3-θειαζολιδινο-2,4-διονης, παρασκευη αυτου και φαρμακοτεχνικες μορφες που περιεχουν αυτo
TH171927A (th) เกลือชนิดใหม่ของ 3-[(3-{[4-(4-มอร์โฟลินิลเมทธิล)-1h-ไพร์รอล-2-อิล]เมทธิลลีน}-2-ออกโซ-2,3-ไดไฮโดร-1h-อินดอล-5-อิล)เมทธิล]-1,3-ไธอะโซลิดีน-2,4-ไดโอน การเตรียมของมันและสูตรผสมที่มีมันประกอบอยู่
TH1501005522A (th) อนุพันธ์ 2-((4-อะมิโน-3-(3-ฟลูออโร-5-ไฮดรอกซีเฟนิล)-1h-ไพราโซโล[3,4-d]ไพริมิดีน-1-อิล)เมทธิล)-3-(2-ไตรฟลูออโรเมทธิล)เบนซิล)ควินาโซลิน-4(3h)-โอน และการใช้สารเหล่านี้เป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3- ไคเนส

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU